Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XLV constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | INCY | Incyte Genomics Inc | 56.5 | 9.00% | 0.33 | 48 | -7.28% | 53 | safe |
| 2 | DXCM | DexCom, Inc. | 52.6 | 3.84% | 0.34 | 32 | -11.10% | 23 | safe |
| 3 | GEHC | GE HealthCare Technologies Inc. Common Stock | 50.7 | 7.51% | 0.57 | 65 | +8.03% | 66 | grey |
| 4 | ZTS | ZOETIS INC. | 49.3 | 8.35% | 0.43 | 69 | +12.78% | 78 | safe |
| 5 | HCA | HCA Healthcare, Inc. | 48.8 | 8.08% | 0.38 | 65 | +7.24% | 77 | grey |
| 6 | CVS | CVS HEALTH CORPORATION | 47.5 | 3.42% | 3.97 | 58 | +8.90% | 56 | distress |
| 7 | BMY | Bristol-Myers Squibb Co. | 46.9 | 7.19% | 0.66 | 51 | +0.13% | 48 | safe |
| 8 | ELV | Elevance Health, Inc. | 45.5 | 6.58% | 0.26 | 66 | +10.82% | 78 | safe |
| 9 | CI | The Cigna Group | 45.0 | 8.17% | -- | 65 | +14.58% | 72 | grey |
| 10 | BSX | Boston Scientific Corp. | 43.7 | 5.27% | 0.73 | 57 | +2.33% | 65 | safe |
| 11 | DVA | DaVita Inc. | 43.3 | 8.01% | 0.43 | 52 | +0.29% | 46 | grey |
| 12 | PFE | Pfizer Inc. | 42.7 | 5.86% | 0.50 | 66 | +6.49% | 62 | safe |
| 13 | RMD | ResMed Inc. | 42.4 | 5.42% | 0.53 | 77 | +13.35% | 78 | safe |
| 14 | ALGN | Align Technology Inc | 40.5 | 5.51% | 0.29 | 60 | +3.94% | 83 | safe |
| 15 | UHS | Universal Health Services, Inc. Class B | 40.1 | 13.03% | 0.27 | 61 | +2.40% | 50 | grey |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | RMD | ResMed Inc. | 61.3 | 9.16% | 9.88 | +13.35% | high |
| 2 | HSIC | Henry Schein Inc | 51.3 | 8.74% | 6.61 | +0.54% | high |
| 3 | INCY | Incyte Genomics Inc | 47.9 | 5.90% | 6.06 | -7.28% | elevated |
| 4 | DVA | DaVita Inc. | 46.7 | 8.26% | 6.50 | +0.29% | elevated |
| 5 | BIIB | Biogen Inc. Common Stock | 44.4 | 4.04% | 4.87 | +10.53% | elevated |
| 6 | CRL | Charles River Laboratories International, Inc. | 44.3 | 6.11% | 2.69 | +24.68% | elevated |
| 7 | ALGN | Align Technology Inc | 41.7 | 5.91% | 4.30 | +3.94% | elevated |
| 8 | UHS | Universal Health Services, Inc. Class B | 41.3 | 6.19% | 2.84 | +2.40% | elevated |
| 9 | PODD | Insulet Corporation | 41.0 | 7.76% | 3.90 | +8.93% | elevated |
| 10 | SOLV | Solventum Corporation | 40.9 | 3.38% | 5.43 | -3.54% | elevated |
| 11 | WAT | Waters Corp | 39.6 | 3.48% | 4.37 | +8.45% | elevated |
| 12 | ZBH | Zimmer Biomet Holdings, Inc. | 39.4 | 5.13% | 4.39 | +7.80% | elevated |
Market cap, valuation, and short-interest metrics are joined to the latest XLV holdings snapshot; each ticker links to its full quote and analysis page.